Zhou Liya / Song Zhiqiang's Team from Peking University Third Hospital Published Findings in The Lancet Infectious Diseases, Providing a New Bactericidal Weapon for Helicobacter pylori Eradication Therapy

Author: Song Zhiqiang, Zhou Liya

https://www.puh3.net.cn/info/1971/159601.htm

        On September 10, 2025, the team of Professor Zhou Liya / Professor Song Zhiqiang from the Department of Gastroenterology, Peking University Third Hospital, leading 40 diagnosis and treatment centers for digestive diseases across the country, online published the latest research findings in the top journal in the field of infectious diseases, The Lancet Infectious Diseases: "Rifazutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial."

        The study, through the world's first Phase III clinical trial, confirmed that the rifazutenizol-based triple therapy has a higher eradication success rate and a lower incidence of adverse reactions, and is less frequent and more convenient to use, providing a new bactericidal weapon for clinical eradication therapy.

        Professor Song Zhiqiang is the first author of the paper, and Professor Zhou Liya is the corresponding author of the paper.

Screenshot of the Paper